Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes

Table 1 Blood biochemistry before and after Canagliflozin treatment

Parameter	Placebo (n = 14)			Canagliflozin (n = 15)			Fixed effects test P value
Parameter	Visit 1	Visit 2	Visit 3	Visit 1	Visit 2	Visit 3	Fixed effects test P value
eGFR	85.22 ± 4.43	79.85 ± 4.22	88.33 ± 4.52	80.24 ± 4.27	81.13 ± 4.56	79.90 ± 4.21	0.31
Creatinine	0.84 ± 0.05	0.94 ± 0.05	0.80 ± 0.06	0.96 ± 0.05	0.88 ± 0.06	0.95 ± 0.05	0.37
HDL	51.56 ± 3.60	52.23 ± 3.66	51.67 ± 3.69	42.96 ± 3.47	46.97 ± 3.48	46.17 ± 3.48	0.28
Cholesterol	163.40 ± 10.09	166.23 ± 10.53	147.76 ± 10.61	167.78 ± 9.74	176.26 ± 9.84	171.57 ± 9.84	0.20
LDL/HDL	1.68 ± 0.15	2.26 ± 0.15	1.60 ± 0.16	2.19 ± 0.15	1.43 ± 0.16	2.08 ± 0.15	0.92
C-reactive protein	1.03 ± 0.2	0.40 ± 0.2	0.92 ± 0.2	0.54 ± 0.2	0.96 ± 0.2	0.63 ± 0.2	0.44
Insulin	2.49 ± 0.21	2.63 ± 0.20	2.71 ± 0.22	2.50 ± 0.20	2.46 ± 0.22	2.56 ± 0.20	0.42
Augmentation Index (AI)	22.14 ± 2.9	24.58 ± 3.1	21.37 ± 3.2	24.2 ± 2.8	23.21 ± 2.9	28.67 ± 2.8	0.17
PWV	11.19 ± 0.64	10.85 ± 0.68	11.42 ± 0.70	9.59 ± 0.66	9.70 ± 0.65	10.12 ± 0.63	0.86
Leptin	39.84 ± 3.34	42.42 ± 3.52	40.28 ± 3.65	28.36 ± 3.30	29.92 ± 3.36	27.79 ± 3.29	0.96
SDF-1α	6.34 ± 0.47	5.74 ± 0.45	5.85 ± 0.47	5.49 ± 0.46	6.41 ± 0.48	5.68 ± 0.44	0.51
3Hydroxy-butyric acid	0.03 ± 0.01	0.0	0.03 ± 0.01	0.01 ± 0.01	0.001 ± 0.01	0.02 ± 0.01	0.75
Acetoacetic acid	0.72 ± 0.25	0.0	0.30 ± 0.27	1.08 ± 0.24	0.05 ± 0.25	0.69 ± 0.24	0.86

ISSN: 1475-2840